Cubist Systematic Strategies, LLC Bellus Health Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $986,761 - $1.29 Million	-120,044 Reduced 61.6%	74,819 $615,000
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $1.32 Million - $1.77 Million	147,364 Added 310.25%	194,863 $2.06 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $156,390 - $242,574	-24,209 Reduced 33.76%	47,499 $439,000
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $281,680 - $404,789	-50,662 Reduced 41.4%	71,708 $493,000
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $574,139 - $905,961	109,152 Added 825.78%	122,370 $985,000
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $18,468 - $45,417	-6,840 Reduced 34.1%	13,218 $81,000
Q4 2020 Feb 16, 2021	SELL	$2.27 - $3.3 $6,356 - $9,240	-2,800 Reduced 12.25%	20,058 $61,000
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $14,654 - $82,312	-6,848 Reduced 23.05%	22,858 $52,000
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $263,789 - $331,221	29,706 New	29,706 $306,000
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $21,813 - $28,781	-3,787 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $23,630 - $33,477	3,787 New	3,787 $24,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.